Rani Therapeutics
[stock_market_widget type=”inline-label” template=”indicator” assets=”RANI” realtime=”true” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”RANI” fields=”market_cap,enterprise_value,pe_ratio,forward_pe_ratio,peg_ratio,price_to_sales_trailing_12_months,price_book,enterprise_revenue,enterprise_ebitda” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”RANI” fields=”volume,open,previous_close,range,52_week_range,beta,target_high_price,shares_outstanding,shares_float” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”chart” template=”line” assets=”RANI” range=”1y” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#000000″ range_selector=”true” axes=”true” cursor=”true” style=”font-size: 14px” api=”yahoo-finance”]
Description
Rani Therapeutics develops oral biologic medicines using an ingestible robotic pill. Its technology is designed to deliver peptides, proteins, and other injectable therapies through the intestinal wall, potentially replacing injections with oral dosing.
Financial Highlights
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”RANI” fields=”profit_margin,operating_margin,return_on_assets,return_on_equity,total_revenue,revenue_per_share,revenue_growth,gross_profit,ebitda,net_income_to_common,quarter_earnings_growth,total_cash,total_cash_per_share,total_debt,operating_cashflow” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
Trading Information
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”RANI” fields=”52_week_low_change_pct,52_week_high,52_week_low,50_day_average,200_day_average,average_volume,average_volume_10_days,shares_outstanding,shares_float,held_percent_insiders,held_percent_institutions,shares_short,short_ratio,annual_dividend_rate,annual_dividend_yield” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
